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We assessed the potential benefits of including systematic
18fluorodeoxyglucose positron emission tomography (FDG-PET) for
detecting tumour recurrence in a prospective randomised trial. Patients (N¼130) who had undergone curative therapy were
randomised to undergo either conventional (Con) or FDG-PET procedures during follow-up. The two groups were matched at
baseline. Recurrence was confirmed histologically. ‘Intention-to-treat’ analysis revealed a recurrence in 46 patients (25 in the FDG-
PET group, and 21 in the Con group; P¼0.50), whereas per protocol analysis revealed a recurrence in 44 out of 125 patients (23 and
21, respectively; P¼0.60). In another three cases, PET revealed unexpected tumours (one gastric GIST, two primary pulmonary
cancers). Three false-positive cases of FDG-PET led to no beneficial procedures (two laparoscopies and one liver MRI that were
normal). We failed to identify peritoneal carcinomatosis in two of the patients undergoing FDG-PET. The overall time in detecting a
recurrence from the baseline was not significantly different in the two groups. However, recurrences were detected after a shorter
time (12.1 vs 15.4 months; P¼0.01) in the PET group, in which recurrences were also more frequently (10 vs two patients) cured by
surgery (R0). Regular FDG-PET monitoring in the follow up of colorectal cancer patients may permit the earlier detection of
recurrence, and influence therapy strategies.
British Journal of Cancer (2008) 98, 875–880. doi:10.1038/sj.bjc.6604263 www.bjcancer.com
Published online 26 February 2008
& 2008 Cancer Research UK
Keywords: FDG PET; CT scan; colon cancer; follow up
                                                   
Colorectal cancer (CRC) is the second most common cause of
cancer-related deaths in Western countries. Most newly-diagnosed
cases already have a tumour invading across the bowel wall with
lymph node invasion (stage III disease) and/or synchronous
metastases (stage IV). Treatment is based on curative surgical
resection (R0). However, approximately half of the patients who
undergo curative R0 surgery go on to develop recurrent disease,
and the median survival time after the operation is no more than 2
years (Griffin et al, 1987; Rodriguez-Moranta et al, 2006). Adjuvant
chemotherapy improves prognosis in these patients, but more than
one-third of them still experience recurrence within the 2 years
following curative therapy (Moertel et al, 1995; Mitry et al, 2005;
Van Cutsem and Costa, 2005). The preferred treatment for patients
with recurrent disease is resection of the metastases in the liver or
lung, and this can result in a 5-year survival rate of 35–40%
(Scheele et al, 1990; Fong et al, 1997). This is why these patients
should be followed-up using either clinical or biological exams, as
well as imaging procedures (Desch et al, 2005; Rodriguez-Moranta
et al, 2006; Sjovall et al, 2007).
Positron emission tomography (PET) using
18fluorodeoxyglu-
cose (FDG) has emerged as a promising diagnostic imaging
method in reassessing recurrent colorectal cancer, and can
potentially improve the selection of patients for surgery, and
hence may have a beneficial impact on the outcome of treatment.
18Fluorodeoxyglucose positron emission tomography (FDG-PET)
detects changes in glucose uptake and metabolism, and also
provides information about the location of a cancer within tissues.
It is now considered to be a sensitive and accurate technique, and
several studies have suggested that it should be carried out before
resection of liver metastases from CRC (Stokkel et al, 2001; van der
Hiel et al, 2001; Fernandez et al, 2004; Truant et al, 2005; Wiering
et al, 2005; Khan et al, 2006).
However, these studies focused mainly on the diagnoses
obtained with FDG-PET, and most of them included only a
retrospective analysis taking clinical management decisions into
account. As far as we know, only one open pilot study has carried
out a prospective analysis of the impact of FDG-PET in patients
already undergoing conventional management, and who were
potentially eligible for resection of colorectal liver metastases
(Ruers et al, 2002). Although CT scanning is the most common
imaging procedure used to follow-up patients, FDG-PET is now
sometimes used in patients with colon or rectal cancer. We do not
know whether FDG-PET provides a more accurate assessment of
the cancer stage than CT-scanning. This study was intended to
assess the contribution of systematic FDG-PET to the detection
and treatment of CRC recurrence following curative surgery in
patients with a high risk of recurrence.
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Between January 2001 and June 2004, 130 patients from seven
teaching hospitals underwent curative R0 surgery for colon or
rectal cancer. They were routinely assessed prospectively at regular
3-monthly intervals up to 24 months after curative surgery, or until
death.
METHODS
At the second visit after curative surgery (6-month follow up visit),
compliance with adjuvant chemotherapy, and the absence of
disease progression and/or missed synchronous metastases were
checked. Patients were randomly divided into two groups: one
group received a conventional work-up (Con) and the other
underwent PET. The baseline date was that of the initial surgery.
The study follow-up started from the ninth month after baseline,
and continued until the twenty-fourth month or the patient’s
death. All patients gave informed consent for the study, which
comprised six visits (see schedule in Figure 1), a physical
examination, biomarker assays (serum CEA or CA19-9, or both),
an ultrasound scan (US) every 3 months (except after 9 and 15
months of follow-up), a chest X-ray every 6 months, and
abdominal CT scans after 9 and 15 months of follow-up. Patients
in the PET group also underwent
18FDG-PET after 9 and 15
months. Various study end points were recorded for the patients:
the overall rate of recurrence in each group after 15-months follow
up, the time until a recurrence was detected by at least one of the
procedures described above, the time to second-line surgical
intervention and/or drug treatment, including either chemother-
apy or palliative therapy and the overall rate of curative surgery, if
any, in each study group.
Biological marker assays as well as US and CT scans were
performed in unselected laboratories by unselected biologists and
radiologists in routine experiments.
18FDG-PET was performed by
selected, trained nuclear physicians using the same machine (at the
Tenon Hospital). Physicians were unaware of the findings of the
CT-scan. Patients fasted for at least 6h before the PET examina-
tion. Patient serum glucose levels were checked to ensure that they
were in the normal range. An FDG solution, with an activity of
2MBq per kg of body mass (corresponding to 150±20MBq for an
average adult), was then infused intravenously. PET imaging was
performed using a C-PET tomograph (Philips, Eindhoven, The
Netherlands) in three-dimensional acquisition mode, and with an
axial field of view of 25cm. The spatial resolution was 4.0mm full-
width at half-maximum. An emission image and transmission
image were recorded at each bed position for 6 and 1min,
respectively, beginning 60min after a tracer injection. The field of
view extended from the base of the skull to the subinguinal region,
requiring six to seven bed positions. The iterative reconstruction
programme was run under X-Windows with a Motif user interface
on a Sun workstation (SUN Microsystems, Palo Alto, CA, USA).
Coronal, sagittal and transaxial images were produced from
emission data with and without attenuation correction, based on
an ordered subsets-expectation maximisation (OSEM) iterative
reconstruction algorithm. Two experienced nuclear medicine
specialists interpreted the slides, and reported whether they
thought a recurrence was present (Yes/No), taking into account
the patient’s history, and the findings of the standard imaging
procedures (not including CT). This yes/no response was classified
as a correct or incorrect diagnosis according to the standard
guidelines for recurrence, as follows. Recurrence was identified
from histological samples (from biopsy or curative surgery) in all
cases except in those with evidence of recurrence consisting of
disseminated metastases or those for whom clinical examination,
tumour markers and imaging procedures (routinely discussed
during a multidisciplinary staff meeting) yielded consistently
positive results. Patients requiring radiofrequency ablation of
hepatic lesions underwent biopsy for histological analyses before
treatment was started. Any discrepancy between the FDG-PET
findings, and those obtained by other imaging procedures or a
physical examination, were taken to be indicative of recurrence,
and this was confirmed by a biopsy. There were several options in
cases in which the FDG-PET results were consistent with
recurrence: (i) continuing with surgery if the image showed one
or a few localised lesions; any additional examinations required by
the surgeon could be performed before surgery, (ii) biopsy of
rectal, colonic, peritoneal, liver, pulmonary or nodular lesions, (iii)
chemotherapy and/or palliative care if required for multiple
recurrent tumours. All imaging findings were correlated with the
subsequent final histological diagnosis, based on findings at
surgery and/or from biopsies.
A new CT-coupled PET machine (PET-CT) became available
from July 2004. This machine provided more effective PET/CT
imaging than the first generation PET scanner; we therefore
stopped recruiting patients to the study after including the one
hundred and thirtieth patient. This was based on ethical concerns
(the chances of patient survival with PET alone vs PET-CT) and
methodological considerations (consistent imaging quality in all
patients).
Statistical analysis
The primary end point was to detect recurrence after 9 and 15
months of follow up in each group, on the basis of the intent-to-
treat principle, that is, data from all randomised patients were
analysed according to the strategy group to which they had been
assigned when randomised. We assumed that the overall
recurrence rate over the 2-year follow-up period would be similar
in the two groups, but that recurrences might be detected earlier in
the PET group. Assuming an overall estimated 30% recurrence
rate, 30 patients with a recurrence need to be included in each
group. By assuming a 30 percent difference in curative treatment
for recurrence between the two arms (an estimated absolute gain of
10% in Con arm, and 40% in PET arm; a¼5% unilateral test and
b¼20%), this requires 180 patients (90 in each arm) over a 2-year
PET and CT scan performed 
Visits   9  15   24 Months
Patients receiving FDG-PET   Surgery for tumour
removal followed by
chemotherapy R
Patients undergoing conventional procedures 
Figure 1 Study scheme.
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sfollow-up period. We compared the number of patients diagnosed
as having a recurrence, the time to onset of recurrence after
curative surgery, and the time until second-line therapy was
started after the confirmed diagnosis of recurrence. Continuous
variables were expressed as mean±s.d., and were compared using
Student’s t-test. Differences in qualitative variables were evaluated
using w
2 test, or the Fisher’s exact test when necessary. We used the
Kaplan–Meier survival analysis and the log-rank test to describe
and compare the time until recurrence or second-line therapy in
the two groups of patients (PET and Con). All patients with
malignant tumours detected during the follow-up were pooled, and
analysed as a single recurrence group. Patients who died and in
whom no recurrence had been detected were considered to have
been in remission with progression-free survival until the time of
their death. In other cases, the progression-free survival period
lasted until the date of recurrence or the date of the patient’s death.
The overall rates for sensitivity, specificity, positive predictive
value and negative predictive values for the CT and PET strategies
were calculated on the basis of the recurrences documented during
the 2-year follow-up period.
RESULTS
One hundred thirty patients (65 in each group) were evaluated in
an ITT analysis; five were excluded from the PP analysis because of
missing data. The two arms were matched with regard to the
characteristics of both the patients and tumours (Table 1). Overall,
the number of patients with a detected recurrence was 44 (23 in the
PET group and 21 the Con group; P¼0.60). Recurrence was
confirmed either by biopsies or surgery in 27 (21.6% in the PP
analysis) of these 44 patients: 15 out of the 60 (25%) patients in the
PET-group, and 12 out of the 65 (18.5%) patients in the Con group
(P¼0.19). Kaplan–Meier curves for the time from baseline until
the detection of a recurrence of the disease during follow-up were
obtained, and ITT analysis performed (Figure 2). There was no
significant difference between the PET and Con groups with regard
to actuarial curves of recurrence (log-rank, P¼0.55); however, for
all the patients with a recurrence, the time from baseline until
detection of the recurrence was significantly shorter (P¼0.01) in
the PET group (12.1±3.6 months) than in the Con group
(15.4±4.9 months). However, if we consider only asymptomatic
patients without elevated serum tumour markers, then a recur-
rence was detected in 34 patients (20 PET group patients and 14 in
the Con group) by imaging procedures (CT, PET, Chest X-Ray,
US). In this case, the time from baseline until the detection of a
recurrence was shorter (although not significantly so) in the PET
group than in the Con group (log-rank test, P¼0.25) (Figure 3).
Impact on therapy management
As specified in the study design, a curative surgical tumour
resection procedure was performed in 17 out of 44 patients (PP
analysis): two in the Con arm and 15 in the PET arm (Table 2). In
11 patients, additional imaging procedures were needed before a
final decision to treat could be reached: four in the PET group and
seven in the Con group. An
18FDG-PET scan was performed in two
patients in the Con arm, because despite elevated tumour marker
levels, no evidence of recurrence was found using Chest X-ray, CT
Table 1 Patient characteristics
Variables/patient group FDG PET Con P
Patients, n 65 65 —
Age, mean (year) (s.d.) 58.1 (11.2) 62.0 (12.1) 0.63
Location
a of tumours
% Colon 56.2 59.4 0.86
% Rectum 43.8 40.6
Differentiation** of the tumour (%)
Good 67.2 57.8
Intermediate 1.6 4.7
Poor 31.2 37.5 0.41
Stage IV (%) 12.1 13.8 0.16
Neo-adjuvant treatment (%)
a
Yes 11.1 13.8
No 88.9 86.2 0.79
Adjuvant treatment (%)
a
Yes 90.5 89.2
No 9.5 10.8 0.99
Time (day) since surgery, mean (s.d.) 231 (60.36) 223.7 (60.36) 0.69
Con¼conventional, FDG-PET¼
18fluorodeoxyglucose positron emission tomography.
a1 missing value. **4 missing values.
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Figure 2 Kaplan–Meier curve for time to recurrence detected in
patients with curative therapy for colon or rectal cancer.
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Figure 3 Kaplan–Meier curve for time to recurrence in asymptomatic
patients without elevated tumour marker levels.
PET and CT scan in colorectal cancer follow-up
I Sobhani et al
877
British Journal of Cancer (2008) 98(5), 875–880 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sScan and US. Curative R0 surgery (Table 3) could be performed in
12 cases, more frequently (Po0.01) in patients in the PET group
(10 out of 23; 43.5%) than in those in the Con group (two out of 21;
9.5%). It is interesting that the FDG-PET examination was the only
imaging procedure to provide a positive finding in six (out of 10)
patients in the PET arm, whereas these recurrences were also
detected by conventional imaging procedures in the other four
patients. In five out of 17 patients who underwent surgery for
curative resection, subsequent pathology reports identified a
second neoplasm in three cases (one case of gastric GIST, and
two cases of primary pulmonary tumours), and no tumour could
be found in two cases (in one case, a left liver lobectomy revealed a
sarcoidosis, and in the other the pathology findings identified an
inflammatory infiltrate in the pelvic floor). Even if the detection of
a second malignant tumour was not considered to be a ‘recurrence’
in the PP analysis for times from baseline until detection, there was
no significant difference between PET and Con patient groups
(log-rank, P¼0.61). Chemotherapy was administered in 39 cases
(19 and 20), and palliative therapy in five cases (two and three) in
the PET and Con groups, respectively. Overall, curative surgery
(R0) was performed or a new course of chemotherapy was started
sooner after baseline in the PET group (14.8±4.1 months) than in
the Con group (17.5±6 months; P¼0.09). At 24 months, nine out
of 44 patients had died: three in the PET-group, and six in the Con
group (Tables 2 and 3).
PET reports compared to all other procedures
Taking all the patients who had undergone an
18FDG-PET, positive
results were recorded in 28 out of 67 patients: (i) a recurrence of
colon or rectum cancer was detected in 22 patients (20 in the PET
group and two in the Con group), (ii) additional primary cancers
were found in three patients, all of them in the PET group; (iii)
false-positive results were recorded for three patients, all in the
PET group, leading to non beneficial procedures (surgery and/or
additional imaging). Conversely, FDG-PET failed to detect
peritoneal carcinomatosis that was subsequently confirmed by
laparoscopy in two patients in the PET group; in one case the
patient had rising serum tumour marker levels, and in the other,
high protein levels and abnormal peritoneal fluid cytology. The
rate of false-negative results was 8% (two of 25) in the PET group.
However, in the Con group, recurrences were correctly identified
in two patients using
18FDG-PET, and in the PET group
recurrences were detected in four patients using
18FDG-PET as
the only imaging procedure. Thus, the overall rates of sensitivity,
specificity, positive predictive value, negative predictive values for
detecting recurrence were 91, 93, 88.6 and 95% respectively in the
conventional arm, and 96, 92.1, 89.2 and 97.2%, respectively in the
PET arm.
DISCUSSION
This is the first prospective controlled randomised study using
FDG-PET to monitor patients with stage III or IV colon or rectal
cancer. We show that FDG-PET is a valuable adjunct to
conventional follow-up in patients with a higher risk of recurrence,
including those who may be candidates for resection of colorectal,
liver or lung metastases. One-third of our patients experienced a
recurrence during a 2-year follow-up period, and the rate of
curative surgery for liver and/or pulmonary metastases resection
was higher in the PET group patients than in the Con group
patients, probably due to earlier detection.
Recurrence of colon and rectal cancer may occur in asympto-
matic patients, and this means that physical examinations,
biological marker assays and imaging procedures must also be
performed (Figueredo et al, 2003; Meyerhardt and Mayer, 2003).
However, improvements in the survival of patients who have had
curative therapy for colon or rectum cancer have been attributable
to intense follow-up programmes including imaging procedures
(Northover et al, 1994; Figueredo et al, 2003). Among these
techniques, CT scans seem to be more sensitive than US for
detecting liver metastases (Pietra et al, 1998; Schoemaker et al,
1998; Secco et al, 2002), and this procedure is now recommended
Table 2 Recurrence (course and management) in patients with stage III
and VI colon and rectal cancer during a 2-year follow-up strategy of
conventional surveillance or additional PET-18FDG
Intention
to Per protocol P
Total, N 130 125
FDG-PET 65 60 —
Con. 65 65
Recurrence, N 46 44
FDG-PET 25 23 —
Con 21 21
Time to recurrence (month) ±s.d.
FDG-PET 12.0±4.9 12.1±3.7
Con 15.3±4.9 15.4±5 0.01
Time to therapy (month)±s.d.
FDG-PET 15.5±5 14.8±4.1 0.09
Con 17.5±6 17.5±6
Biopsies and surgery, N (% over total) 27 (20.8) 27 (21.6)
PET-18FDG 15 (23) 15 (25)
Con 12 (18.5) 12 (18.5) 0.67
Surgery operation, N (% over
recurrences)
17 (37) 17 (38.6)
PET-18FDG 15 (60) 15 (65)
Con 2 (9.5) 2 (9.5) o0.0001
R0 curative, N (% over recurrences) 12 (26) 12 (27.3)
PET-18FDG 10 (40) 10 (43.8)
Con 2 (9.5) 2 (9.5) o0.01
Death, N (% over recurrences) 9 (20.5)
FDG-PET — 3 (13)
Con — 6 (28.5) 0.33
Time to (months)
FDG-PET — 8.4, 21.3, 23.2
Con — 9.1, 9.4, 10, 12, 13,
21.3
Con¼conventional, FDG-PET¼
18fluorodeoxyglucose positron emission tomography.
Table 3 Characteristics of patients undergoing R0 surgery for recurrence
during a 2-year follow-up period in patients with rectal or colon cancer
Con arm PET arm Total
Total, N 2
a 10
a 12
pTNM staging at baseline
stage III 1 8 9
stage IV 1 2 3
Site of recurrence
Abdominal, liver 2 6 8
Other 0 2 2
Thoracic, pulmonary 0 2 2
Time to therapy (month) ±s.d. 9.4 & 16.3 12.2±3.6 13.8±4.3
Death, up to the end of study 0 0 0
Con¼conventional, PET¼positron emission tomography.
aAdditional imaging
procedures including MRI or PET arm were needed to best characterise sites and
numbers of metastasis.
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missed (Holt et al, 2006). Thus, the possibility of performing R0
curative surgery if the only liver imaging performed is CT scanning
appears to be limited. An accurate imaging procedure for the
detection of lung metastases is also necessary. although, CT of the
chest did not appear to be the most cost-effective procedure
(Goldberg et al, 1998).
Nevertheless, detection of a recurrence should lead to curative
therapy with an aggressive surgical approach. This requires the
early detection of recurrences in asymptomatic patients whether
tumour marker levels are elevated or not. In this study, adding
systematic FDG-PET to the routine follow-up procedures resulted
in a higher number of curative surgical interventions being
performed in the PET group than in the Con group. This
significant difference is probably due to the delayed detection of
recurrence and the additional examinations required to support
decisions about therapeutic strategy in the Con group, and to the
detection of three additional primary cancers in the PET group.
These were also consistent with the findings of another prospective
uncontrolled study in which
18FDG-PET was used for patient
monitoring (Ruers et al, 2002), and in which there were two times
as many deaths in the Con group as in the PET group. Although,
our findings suggest that combining the use of whole-body
FDG-PET with conventional anatomic imaging may significantly
improve patient survival, the number of patients investigated does
not allow us to reach a firm conclusion about this.
Recent PET machines have a higher detection rate for small
tumours than the machine used in this study, and coupled PET-CT
appears to provide more accurate diagnoses than performing the
two examinations separately (Cohade et al, 2003; Even-Sapir et al,
2004; Kamel et al, 2004; Nakamoto et al, 2007). It permits a more
accurate interpretation, and improves the detection of lesions.
Thus, we would expect combined PET-CT to make it easier to
determine the stage of the disease correctly. Further investigation
with a greater number of patients and PET-CT procedure is
required to find out whether the early detection of recurrences
during follow-up screening is cost-effective.
In summary, using this new follow-up strategy increased the rate
of curative resection (R0) in patients by allowing us to detect
CRC recurrences at an earlier stage. We would therefore expect
improved patient survival if such a follow-up programme was
undertaken. We now need to assess the cost-effectiveness of
strategies including the systematic use of FDG PET/CT in patients
who have developed stage III and VI colon and rectum cancer
following curative surgery.
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